Treatment of Extensive Non-Small Cell Lung Cancer: Standard Dose Cisplatin Versus High-Dose Cisplatin in Hypertonic Saline Alone Versus High-Dose Cisplatin/Mitomycin-C

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group.

DR Gandara;J Crowley;RB Livingston;EA Perez;CW Taylor;G Weiss;JR Neefe;LF Hutchins;RW Roach;SM Grunberg;TJ Braun;RB Natale;SP Balcerzak Classic Papers and Current Comments 2(1):178-184

Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: A phase III study of the Southwest Oncology Group.

DR Gandara;J Crowley;RB Livingston;EA Perez;CW Taylor;G Weiss;JR Neefe;LF Hutchins;RW Roach;SM Grunberg;TJ Braun;RB Natale;SP Balcerzak JCO 11(5):873-878

Comparison of standard dose cisplatin, high dose cisplatin, and high dose cisplatin plus mitomycin in metastatic non small cell lung cancer: Preliminary results of a phase II study. UC Davis/VAMC Martinez and Southwest Oncology Group.

DR Gandara;MT Tanaka;J Crowley;RB Livingston ASCO 10:246(#843)